COYA 302 is a therapy that combines two different biologics — low-dose IL-2 and CTLA-4 Ig. Complex diseases demand complex treatment solutions, and the combination biologic approach is key in our hypothesis to treat neurodegenerative diseases like ALS. Learn more about the approach in this article from Bioprocess Online: https://lnkd.in/emyC3eys $COYA #CoyaTherapeutics #CombinationBiologics
Coya Therapeutics, Inc.
生物技术研究
Houston，Texas 3,600 位关注者
Unleashing the power of Tregs to tackle neurodegenerative and autoimmune diseases.
关于我们
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. Coya’s mission is focused on the advancement of innovative therapeutic approaches to address the significant unmet medical needs of patients with serious neurodegenerative, autoimmune, and metabolic diseases. For more information about Coya, please visit www.coyatherapeutics.com.
- 网站
-
https://www.coyatherapeutics.com
Coya Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Houston，Texas
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
获取路线
5850 San Felipe St
Suite 500
US，Texas，Houston，77057
Coya Therapeutics, Inc.员工
动态
-
Coya Therapeutics CEO Dr. Arun Swaminathan issued a letter to shareholders this morning to discuss his thoughts on Coya and the future of the company heading into 2025. Read more in our latest press release: https://lnkd.in/eGJP7d_Z $COYA #CoyaTherapeutics #EndALS #EndFTD
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
ir.coyatherapeutics.com
-
Coya Therapeutics announced this morning unaudited third quarter 2024 financial results, as well as a corporate update. Read more in the latest press release here: https://lnkd.in/gduiJeAr $COYA #CoyaTherapeutics?
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
ir.coyatherapeutics.com
-
Coya Therapeutics announces that, as previously disclosed, Arun Swaminathan, Ph.D., has been promoted to Chief Executive Officer, effective today, November 1. He brings a wealth of strategic, business development, operational, and deal-making experience to help guide Coya in its next phase of corporate growth. Arun said: "We believe our combination therapeutic approach targeting neuroinflammation can unlock a new paradigm in neurodegenerative treatment. We are encouraged by data from the Phase 2 investigator-initiated trial in patients with mild to moderate Alzheimer’s disease treated with low-dose interleukin-2 (LD IL-2), shared at CTAD, validating our Treg platform." Read more in our latest press release: https://lnkd.in/egtQah8t $COYA #CoyaTherapeutics #CEO
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
ir.coyatherapeutics.com
-
#ICYMI, Coya Therapeutics announced positive results yesterday of an investigator initiated double-blind study of low-dose IL-2 in Alzheimer’s Disease, co-sponsored with Houston Methodist, Alzheimer's Association?, Bill & Melinda Gates Foundation, and National Institute on Aging (NIA) with support provided by Coya. The study strongly supports Coya’s approach to address #neurodegenerative diseases and once-a-month dosing, underscoring the importance of appropriate IL-2 dosing for maintaining Treg functionality and its associated effects on CSF biomarkers and cognitive outcomes. "Alireza Faridar, M.D., lead investigator and neurologist at Houston Methodist, saw the sustained expansion of Tregs throughout the period in which patients received IL-2. On the Treg endpoints, IL-2 performed best when given every four weeks, rather than every two weeks. The less frequent dosing regimen also looked better on the exploratory efficacy endpoints." Read more in this important article from Fierce Biotech: https://lnkd.in/eh-SJH7M $COYA #CoyaTherapeutics #Research #EndALZ
Coya touts partnership potential as IL-2 prospect comes through small Alzheimer's study
fiercebiotech.com
-
Progress around novel therapies informed by the biology of aging continues at CTAD Clinical Trials on Alzheimer's Disease. ADDF-funded Coya Therapeutics, Inc. reported positive results from their phase 2 trial of a novel drug that aims to enhance the function of regulatory T cells, which suppress #immune responses, showing the drug was safe and well-tolerated in #Alzheimers patients. This is one of many drugs in development that has the potential to be used in tandem with #antiamyloid therapies, moving us closer to treating Alzheimer's with a combination therapy approach. #CTAD24 https://bit.ly/3NKNIde via Reuters
-
-
Some quick stats from the important IL-2 Alzheimer’s study released today: 1. It met primary and secondary endpoints for safety and Treg cell population enhancement demonstrating target engagement. 2. Exploratory endpoints demonstrated stabilization of cognitive function in the every four-week dosing (LD IL-2 q4wks) treatment vs. placebo, which illustrated cognitive decline. 3. The findings support advancing LD IL-2 q4wks and LD IL-2 q4wks combination approaches in future studies. Find out more in the COYA presentation here: https://lnkd.in/eEwfk-VY $Coya #CoyaTherapeutics #EndALZ #Research
-
-
MAJOR NEWS: Coya Therapeutics announces positive results of a double-blind study of low-dose IL-2 in Alzheimer’s Disease at CTAD in Madrid, co-sponsored with Houston Methodist, Alzheimer's Association?, Bill & Melinda Gates Foundation, and the National Institute on Aging (NIA). Read the full press release here: https://lnkd.in/eZVEVUVg $COYA #CoyaTherapeutics #EndALZ #Research
-
-
Coya Therapeutics is excited to announce that we have been selected as a finalist for the Fierce Life Sciences Events Innovation Awards in the category Biotech Innovation! This recognition highlights the incredible work our team has done with COYA 302. Check out the full list of finalists here and mark your calendars for when the winners will be announced in December: https://lnkd.in/epdDMtPC #FierceLifeSciencesAwards #FierceInnovationAwards #CoyaTherapeutics
-
-
Coya Therapeutics is excited to share that CEO Howard Berman, PhD has been recognized on the PharmaVoice 100 list as an inspiring leader in the life-sciences space! Congratulations Howard, we are fortunate to have such a talented founder. Check out the full list here: https://lnkd.in/eB9K8vFe $COYA #CoyaTherapeutics #PV100 #LifeSciences #Pharma #PharmaVoice100 #PharmaLeaders
-